147 related articles for article (PubMed ID: 10969931)
1. Neurofibromatosis type 1 and precocious puberty.
Virdis R; Sigorini M; Laiolo A; Lorenzetti E; Street ME; Villani AR; Donadio A; Pisani F; Terzi C; Garavelli L
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():841-4. PubMed ID: 10969931
[TBL] [Abstract][Full Text] [Related]
2. Growth and pubertal disorders in neurofibromatosis type 1.
Virdis R; Street ME; Bandello MA; Tripodi C; Donadio A; Villani AR; Cagozzi L; Garavelli L; Bernasconi S
J Pediatr Endocrinol Metab; 2003 Mar; 16 Suppl 2():289-92. PubMed ID: 12729406
[TBL] [Abstract][Full Text] [Related]
3. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
[TBL] [Abstract][Full Text] [Related]
4. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years.
Paul D; Conte FA; Grumbach MM; Kaplan SL
J Clin Endocrinol Metab; 1995 Feb; 80(2):546-51. PubMed ID: 7852518
[TBL] [Abstract][Full Text] [Related]
6. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study.
Carmi D; Shohat M; Metzker A; Dickerman Z
Pediatrics; 1999 Jun; 103(6 Pt 1):1257-62. PubMed ID: 10353939
[TBL] [Abstract][Full Text] [Related]
7. Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature.
Kocova M; Kochova E; Sukarova-Angelovska E
BMC Endocr Disord; 2015 Dec; 15():82. PubMed ID: 26666878
[TBL] [Abstract][Full Text] [Related]
8. Adult height after cranial irradiation for optic pathway tumors: relationship with neurofibromatosis.
Huguenin M; Trivin C; Zerah M; Doz F; Brugieres L; Brauner R
J Pediatr; 2003 Jun; 142(6):699-703. PubMed ID: 12838200
[TBL] [Abstract][Full Text] [Related]
9. Adult height in advanced puberty with or without gonadotropin hormone releasing hormone analog treatment.
Couto-Silva AC; Adan L; Trivin C; Brauner R
J Pediatr Endocrinol Metab; 2002 Mar; 15(3):297-305. PubMed ID: 11924932
[TBL] [Abstract][Full Text] [Related]
10. Precocious puberty in children with neurofibromatosis type 1.
Habiby R; Silverman B; Listernick R; Charrow J
J Pediatr; 1995 Mar; 126(3):364-7. PubMed ID: 7869193
[TBL] [Abstract][Full Text] [Related]
11. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
Lanes R; Soros A; Jakubowicz S
J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
[TBL] [Abstract][Full Text] [Related]
12. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.
Klein KO; Barnes KM; Jones JV; Feuillan PP; Cutler GB
J Clin Endocrinol Metab; 2001 Oct; 86(10):4711-6. PubMed ID: 11600530
[TBL] [Abstract][Full Text] [Related]
13. Adult height in precocious puberty after long-term treatment with deslorelin.
Oerter KE; Manasco P; Barnes KM; Jones J; Hill S; Cutler GB
J Clin Endocrinol Metab; 1991 Dec; 73(6):1235-40. PubMed ID: 1955504
[TBL] [Abstract][Full Text] [Related]
14. Near final height after GnRH agonist treatment in central precocious puberty.
Micillo M; Salerno M; Officioso A; Perna E; Gasparini N; Pisaturo L; Di Maio S
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():787-90. PubMed ID: 10969922
[TBL] [Abstract][Full Text] [Related]
15. Precocious puberty and statural growth.
Carel JC; Lahlou N; Roger M; Chaussain JL
Hum Reprod Update; 2004; 10(2):135-47. PubMed ID: 15073143
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty.
Rizzo V; De Sanctis V; Corrias A; Fortini M; Galluzzi F; Bertelloni S; Guarneri MP; Pozzan G; Cisternino M; Pasquino AM
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():781-6. PubMed ID: 10969921
[TBL] [Abstract][Full Text] [Related]
17. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group.
Partsch CJ; Heger S; Sippell WG
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():747-58. PubMed ID: 10969917
[TBL] [Abstract][Full Text] [Related]
18. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience.
Mul D; Oostdijk W; Otten BJ; Rouwé C; Jansen M; Delemarre-van de Waal HA; Waelkens JJ; Drop SL
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():765-72. PubMed ID: 10969919
[TBL] [Abstract][Full Text] [Related]
19. Precocious puberty associated with neurofibromatosis and optic gliomas. Treatment with luteinizing hormone releasing hormone analogue.
Laue L; Comite F; Hench K; Loriaux DL; Cutler GB; Pescovitz OH
Am J Dis Child; 1985 Nov; 139(11):1097-100. PubMed ID: 3933329
[TBL] [Abstract][Full Text] [Related]
20. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.
Pasquino AM; Pucarelli I; Roggini M; Segni M
J Clin Endocrinol Metab; 2000 Feb; 85(2):619-22. PubMed ID: 10690865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
